RE: News Release Anyone knows what the sales figure of this was if there were any? Or was it still in the trial process? Any knowledge of the data? Were they good? What do you think the impact will be? NZ, what do you base on in jumping to the verdict that this is "bad" news.
I see the recumbant FSH as a competitor for our Fillotropin. By signing the license right for it, I viewed it as a defensive measure. But if the sales figure or trial data is not that good, perhaps BNC start to realize that it is not that much of a threat anyway.
I also think that this might be a move by BNC to consolidate their available cash and their man-power and sales rep. This might be the first step in their attempt to cut the cash burn. And with the upcoming new products and the newly launched Immunocidin and Sin Susto, , they will need sales rep.
JMHO.